Vonjo is owned by Cti Biopharma Corp.
Vonjo contains Pacritinib Citrate.
Vonjo has a total of 3 drug patents out of which 0 drug patents have expired.
Vonjo was authorised for market use on 28 February, 2022.
Vonjo is available in capsule;oral dosage forms.
Vonjo can be used as use of pacritinib for inhibiting janus associated kinase 2(jak2); treatment of myelofibrosis with pacritinib, treatment of myelofibrosis with pacritinib; use of pacritinib for inhibiting janus associated kinase 2(jak2).
Drug patent challenges can be filed against Vonjo from 2026-02-28.
The generics of Vonjo are possible to be released after 25 March, 2030.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US8153632||CTI BIOPHARMA CORP||Oxygen linked pyrimidine derivatives|| |
(5 years from now)
|US8980873||CTI BIOPHARMA CORP||11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[22.214.171.124(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt|| |
(6 years from now)
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US9573964||CTI BIOPHARMA CORP||Oxygen linked pyrimidine derivatives|| |
(4 years from now)
|Orphan Drug Exclusivity (ODE)||Feb 28, 2029|
|New Chemical Entity Exclusivity (NCE)||Feb 28, 2027|
Drugs and Companies using PACRITINIB CITRATE ingredient
NCE-1 date: 2026-02-28
Market Authorisation Date: 28 February, 2022
Treatment: Use of pacritinib for inhibiting janus associated kinase 2(jak2); Treatment of myelofibrosis with pacritinib
Korea, Republic of
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic